TLR4−/− deletion or inhibition has been shown to improve endothelial dysfunction in mice caused by angiotensin II delivery or type II diabetes (Liang et al., 2013; Hernanz et al., 2015). This evidence concerns the gene AGT and type 2 diabetes mellitus.